LYEL

Lyell Immunopharma, Inc. (LYEL) | Rumor.io

Lyell Immunopharma

LYEL

Attention (50-day avg)0%

Attention rank (50-day avg)#2,660

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.75

Market capitalization238.7M

Earnings per share-12.7

Dividend yield (TTM)—

Revenue (annual)36K

Net income (annual)-274.4M

Social

What share of all stock conversation is about LYEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% new	0% +0	0% 0	0% 0

Mar 9

Lyell Immunopharma, Inc. (LYEL) has announced the closing of an additional $50 million tranche of equity private placement and appointed Smital Shah as Chief Financial and Business Officer.
ARCH Venture Fund XIII, L.P. has purchased 488,090 shares of LYEL at $25.61, worth $12,499,984.90.
Smital Shah has been appointed as Chief Financial and Business Officer of LYEL, effective March 9, 2026, with a salary of $500,000 and additional stock options for 140,000 shares.

Generated by AI

Sentiment

Of the messages about LYEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	91.3% +2.79
Bearish	—	—	0% 0	8.7% -2.79

Jul 29

$LYEL has a strong chart with a potential breakout at 35-36.
LYEL is considered a safe bet with a strong chart and favorable fundamentals.
LYEL's current valuation is undervalued compared to its fundamentals.

Generated by AI

Topics

Of the messages about LYEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.66%
Analysts	—	—	0%	11.59%
Technical Analysis	—	—	0%	6.1%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	3.66%

Oct 6

Lyell Immunopharma's IND for LYL845, a TIL product candidate, has been cleared by the FDA for solid tumors.
The product candidate is enhanced with Lyell Immunopharma's novel epigenetic reprogramming technology.
Lyell Immunopharma will present preclinical data highlighting new T-cell reprogramming technologies and its growing pipeline at the Society for Immunotherapy of Cancer (SITC22).

Generated by AI

Community

Of the messages about LYEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.48%	13.76%
Newcomers	100%	100%	93.52%	86.24%

Nov 13

Newcomers are focusing on the potential rerate of LYEL, comparing it to NXXT's daily flow.
Accumulation signals are bullish, indicating a potential increase in $LYEL's price.
BlackRock's silent buying of LYEL is being monitored, with some seeing it as a rerate moment.

Generated by AI

News

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

16d agoYahoo Finance

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c

19d agoYahoo Finance

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress

1mo agoInvesting.com

Also Discussed

Investors talking about LYEL also mention

#	Name	Attention
1	PMNT - Perfect Moment Ltd. Common Stock	——
2	Installed Building Products, Inc.IBP	0%0
3	Kontoor Brands Inc.KTB	0%0
4	Greif Inc. Class A Common StockGEF	0%0
5	CIVI - Civitas Resources, Inc.	——
6	IHS Holding Ltd.IHS	0%0
7	Dream Finders Homes Inc Class A Common StockDFH	0%+0
8	Surgery Partners Inc.SGRY	0%0
9	Melco Resorts & Entertainment Ltd. ADRMLCO	0%0
10	STAI - ScanTech AI Systems Inc.	——

Lyell Immunopharma, Inc.

Healthcare
Biotechnology

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing next-generation CAR T-cell therapies for cancer. The company is advancing a pipeline of product candidates designed to improve T-cell performance by helping cells resist exhaustion, persist longer, and maintain stronger tumor-fighting activity in challenging cancer environments. Its current programs target both hematologic malignancies and solid tumors, with work spanning blood cancers such as large B-cell lymphoma and solid-tumor indications including colorectal cancer. Lyell Immunopharma combines genetic and epigenetic T-cell reprogramming technologies with manufacturing capabilities to support product development and clinical testing. Based in South San Francisco, California, the company plays a role in the broader immunotherapy market by focusing on engineered cell-based treatments intended to address major unmet needs in oncology.

Website

Location

201 Haskins Way

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about LYEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% new	0% +0	0% 0	0% 0

Mar 9

Lyell Immunopharma, Inc. (LYEL) has announced the closing of an additional $50 million tranche of equity private placement and appointed Smital Shah as Chief Financial and Business Officer.
ARCH Venture Fund XIII, L.P. has purchased 488,090 shares of LYEL at $25.61, worth $12,499,984.90.
Smital Shah has been appointed as Chief Financial and Business Officer of LYEL, effective March 9, 2026, with a salary of $500,000 and additional stock options for 140,000 shares.

Generated by AI

Sentiment

Of the messages about LYEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	91.3% +2.79
Bearish	—	—	0% 0	8.7% -2.79

Jul 29

$LYEL has a strong chart with a potential breakout at 35-36.
LYEL is considered a safe bet with a strong chart and favorable fundamentals.
LYEL's current valuation is undervalued compared to its fundamentals.

Generated by AI

Topics

Of the messages about LYEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.66%
Analysts	—	—	0%	11.59%
Technical Analysis	—	—	0%	6.1%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	3.66%

Oct 6

Lyell Immunopharma's IND for LYL845, a TIL product candidate, has been cleared by the FDA for solid tumors.
The product candidate is enhanced with Lyell Immunopharma's novel epigenetic reprogramming technology.
Lyell Immunopharma will present preclinical data highlighting new T-cell reprogramming technologies and its growing pipeline at the Society for Immunotherapy of Cancer (SITC22).

Generated by AI

Community

Of the messages about LYEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.48%	13.76%
Newcomers	100%	100%	93.52%	86.24%

Nov 13

Newcomers are focusing on the potential rerate of LYEL, comparing it to NXXT's daily flow.
Accumulation signals are bullish, indicating a potential increase in $LYEL's price.
BlackRock's silent buying of LYEL is being monitored, with some seeing it as a rerate moment.

Generated by AI

Lyell Immunopharma

Social

Mar 9

Jul 29

Oct 6

Nov 13

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy

Lyell Immunopharma CMO David Shook sells $6,350 in shares

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress

Also Discussed

Lyell Immunopharma, Inc.

Company Information

Location

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy

Lyell Immunopharma CMO David Shook sells $6,350 in shares

Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress

Also Discussed

Social

Mar 9

Jul 29

Oct 6

Nov 13